A prospective, open-label study to evaluate symptomatic remission in schizophrenia with long acting risperidone microspheres (Risperdal Consta)

Trial Profile

A prospective, open-label study to evaluate symptomatic remission in schizophrenia with long acting risperidone microspheres (Risperdal Consta)

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2009

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Janssen Pharmaceutica
  • Most Recent Events

    • 29 Jan 2009 Actual end date (Apr 2007) added as reported by ClinicalTrials.gov.
    • 29 Jan 2009 Planned number of patients changed from 745 to 527 as reported by ClinicalTrials.gov.
    • 29 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top